Antibodies Partners with Dr. Gregory Kapatos, Producer of Highly-Cited Mouse Monoclonal anti-Tyrosine Hydroxylase (LNC1), to Expand Product Portfolio

Antibodies Incorporated is proud to announce our collaboration with Gregory Kapatos, Ph.D. to develop antibodies against critical targets modulating gene expression. Dr. Kapatos personally developed the highly-cited anti-tyrosine hydroxylase antibody LNC1 and brings a wealth of experience to help guide our antibody development efforts.

About Dr. Kapatos

Dr. Kapatos is currently Emeritus Professor of Molecular Medicine and Genetics at Wayne State University School of Medicine. Dr. Kapatos has published over 100 scientific articles and book chapters and has made significant contributions to our understanding of how monoamine neurotransmitter biosynthesis is regulated as well as to current models of human drug abuse.

The Project

Dr. Kapatos will work with Antibodies Incorporated and Aves Labs to develop new products designed to provide researchers with a broad range of tools to advance cell science in the genomics era.

Dr. Kapatos developed the mouse monoclonal antibody LNC1, which has been cited (via sales through multiple commercial partners) in over 2,000 publications over the last 30 years. As part of this collaboration, this antibody to tyrosine hydroxylase will be made available directly to end users through Antibodies Incorporated.

The LNC1 Clone


LNC1 is an antibody which can be used to detect Tyrosine Hydroxylase (TH). TH is the rate-limiting enzyme in the synthesis of the catecholamine neurotransmitters dopamine, epinephrine, and norepinephrine. In all species, catecholamine synthesis is regulated by the interaction of TH with its cofactor, tetrahydrobiopterin (BH4) and the substrates L-tyrosine and molecular oxygen.

Get anti-Tyrosine Hydroxylase (LNC1) in Regular or Trial Size

Unlike TH in non-primate species, four human TH mRNA splice variants (hTH1-hTH4) have been isolated. These variants are identical in their catalytic domain, but differ in their N-terminal regulatory domains. LNC1 reacts with the catalytic domain of TH and thus with all four forms of human TH.

The role of TH in the synthesis of catecholamine neurotransmitters suggests a correlation between the enzyme and a number of neuropathogenic diseases characterized by irregular catecholamine levels, such as Parkinson's disease, schizophrenia, and dystonia, as well as a variety of cardiovascular diseases.

Why This Collaboration Matters

Antibodies is delighted to have someone with Dr. Kapatos’ depth of experience join our team. When asked about the partnership, Dr. Kapatos said, “I am thrilled to be joining Antibodies Incorporated and Aves Labs. One thing that my years of research has shown me is that high-quality research demands the use of high-quality antibodies. LNC1 is a testament to that, and I look forward to working with the team to support their mission of advancing science through the addition of new and innovative products to their already impressive portfolio."

Advance Your Innovation with Antibodies Incorporated and Aves Labs


NeuroMab logoExtend your reach with these highly-validated antibodies developed in collaboration with leading neuroscientists.

Aves Labs' selection of neural markers and epitope tag antibodies are ideal for performing Western Blots, ELISAs, Immunoprecipitation, and Immunohistochemistry(IHC) or Immunocytochemistry(ICC).

Custom Services

Antibodies Incorporated awarded contract for 5-year project to develop up to 100 mouse monoclonal antibodies to support discovery of novel cancer biomarkers and therapeutics.